Review of efficacy of rosuvastatin 5 mg

International Journal of Clinical Practice

Volumn 59, Issue 1, 2005, Pages 92-101

  Teramoto, Tamio ^a,c   Watkins, C ^b  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ASTRAZENECA   (United Kingdom)

^c NONE   (Japan)

Author keywords

Coronary heart disease; HDL C; LDL C; Lipid lowering therapy; Rosuvastatin

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; LIVER DYSFUNCTION; MUSCLE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 13844312467     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2005.00346.x     Document Type: Review

References (48)

1. Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. JAMA 2002; 288: 2569-78.
2. Saito I, Ozawa H, Aono H et al. Trends in fatal coronary heart disease among people aged 25-74 years in Oita City, Japan, from 1987 to 1998. J Clin Epidemiol 2002; 55: 469-76.
3. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 1995; 76: 69C-77C.
4. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
5. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
6. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333 1301-7.
7. Scandinavian Simvastatin Survival Study Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
8. Mabuchi H, Kita T, Matsuzaki M et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 2002; 66: 1096-100.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
10. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
11. Hata Y, Mabuchi H, Saito Y et al. Report of the Japan Atherosclerosis Society (JAS) guideline for diagnosis and treatment of hyperlipidemia in Japanese adults. J Atheroscler Thromb 2002; 9 1-27.
12. J-LAP Investigators, Teramoto T, Kashiwagi A, Mabuchi H. The current status of lipid-lowering therapy for hyperlipidemia in Japan: Japan Lipid Assessment Program (J-LAP). Presented at the XIII International Symposium on Atherosclerosis; September 28-October 2, 2003; Kyoto, Japan.
13. Pearson TA, Laurora I, Chu H et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-67.
14. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-72.
15. Sueta CA, Chowdhury M, Boccuzzi SJ et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary heart disease. Am J Cardiol 1999; 83: 1303-7.
16. Foley KA, Simpson RJ, Crouse JR et al. Efficacy of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003; 92: 79-81.
17. Brown WV. Novel approaches to lipid lowering: what is on the horizon? Am J Cardiol 2001; 87: 23B-27B.
18. McTaggart F, Buckett L, Davidson R et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001; 87 (Suppl.): 28B-32B.
19. Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002; 20: 303-28.
20. Schuster H. Rosuvastatin a highly effective HMG-CoA reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients. Cardiology 2003; 99: 126-39.
21. Saito Y, Goto Y, Dane A, Strutt K, Raza A. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 2003; 10(6): 329-36.
22. Yamamoto A, Arakawa K, Sasaki J et al. for the Rosuvastatin Dose-Ranging Trials Group. Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study. J Atheroscler Thromb 2002; 9: 48-56.
23. Blasetto JW, Stein EA, Brown WV et al. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003; 91(Suppl.): 3C-10C.
24. Strutt KS, Caplan R, Hutchison H et al. More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin or simvastatin therapy. Circ J 2004; 68: 107-13.
25. Gordon T, Castelli WP, Hjortland MC et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-14.
26. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 56-64.
27. Francis MC, Frohlich JJ. Coronary artery disease in patients at low risk - apolipoprotein AI as an independent risk factor. Atherosclerosis 2001; 155: 165-70.
28. Talmud PJ, Hawe E, Miller GJ et al. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002; 22: 1918-23.
29. Bittner V, Hardison R, Kelsey SF et al. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 2002; 106: 2537-42.
30. Walldius G, Jungner I, Holme I et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
31. Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 1998; 81 (4A): 26B-31B.
32. AstraZeneca LP. Macclesfield, Cheshire, UK: Alderley Park, 1998-2003. Data on file.
33. Ballantyne CM, Stein EA, Paoletti R et al. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol 2003; 91: 25C-27C.
34. Sacks FM. Clinical usefulness of HDL cholesterol as a target to lower risk of coronary heart disease. Br J Cardiol 2003; 10 (4): 297-304.
35. Brewer HB. Benefit-risk assessment of rosuvastatin 10-40 milligrams. Am J Cardiol 2003; 92 (Suppl.): 23K-29K.
36. Shepherd J, Hunninghake DB, Harris S et al. Safety profile of rosuvastatin in an international phase II/III clinical trial program. Presented at the XIII International Symposium on Atherosclerosis; September 28-October 2 2003, Kyoto, Japan.
37. Baycol (cerivastatin sodium tablets). In: Physicians' Desk Reference, 54th edn. Montvale, NJ: Medical Economics Co, 2000: 675-7.
38. Lescol (fluvastatin sodium). In: Physicians' Desk Reference, 58th edn. Montvale, NJ: Medical Economics Co, 2004: 2274-8.
39. Lipitor (atorvastatin calcium). In: Physicians' Desk Reference, 58th edn. Montvale, NJ: Medical Economics Co, 2004: 2606-10.
40. Mevacor (lovastatin). In: Physicians' Desk Reference, 58th edn. Montvale, NJ: Medical Economics Co, 2004: 2025-30.
41. Pravachol (pravastatin sodium). In: Physicians' Desk Reference, 58th edn. Montvale, NJ: Medical Economics Co, 2004: 1069-74.
42. Zocor (simvastatin). In: Physicians' Desk Reference, 58th edn. Montvale, NJ: Medical Economics Co, 2004: 2113-8.
43. US Food and Drug Administration. Summary Basis for Approval of the atorvastatin New Drug Application 20-702. Washington, DC; December 17, 1996.
44. US Food and Drug Administration. Summary Basis for Approval of the cerivastatin New Drug Application 20-740. Washington, DC; May 24, 1999.
45. US Food and Drug Administration. Summary Basis for Approval of the fluvastatin New Drug Application 20-261. Washington, DC; March 8, 1999.
46. US Food and Drug Administration. Summary Basis for Approval of the lovastatin New Drug Application 19-643. Washington, DC; June 25, 1997.
47. US Food and Drug Administration. Summary Basis for Approval of the pravastatin New Drug Application 19-898. Washington, DC; April 15 1997.
48. US Food and Drug Administration. Summary Basis for Approval of the simvastatin New Drug Application 19-766/S-028. Washington, DC; July 10 1998.